About Ubiquitin carboxyl-terminal hydrolase isozyme L1
Ubiquitin carboxyl-terminal hydrolase isozyme L1 (UCHL1) is a protein
from Homo sapiens identified by UniProt accession
P09936, 223 residues long.
MolForge cross-references it against 0 known binders and
686 disease associations.
Target properties
| Protein name | Ubiquitin carboxyl-terminal hydrolase isozyme L1 |
|---|
| UniProt accession | P09936 |
|---|
| Gene | UCHL1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 223 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (686)
Diseases linked to this target (Open Targets).
- early-onset progressive neurodegeneration-blindness-ataxia-spasticity syndrome · score 0.80
- Early-onset progressive neurodegeneration - blindness - ataxia - spasticity · score 0.73
- Young adult-onset Parkinsonism · score 0.64
- Spastic paraplegia · score 0.48
- glioblastoma multiforme · score 0.19
- genetic disorder · score 0.18
- neoplasm · score 0.11
- non-small cell lung carcinoma · score 0.11
- cancer · score 0.10
- myocardial infarction · score 0.10
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P09936-F1 | alphafold | PREDICTED | 93.60 | — |
Amino-acid sequence (223 residues)
MQLKPMEINP EMLNKVLSRL GVAGQWRFVD VLGLEEESLG SVPAPACALL LLFPLTAQHE NFRKKQIEEL KGQEVSPKVY FMKQTIGNSC GTIGLIHAVA NNQDKLGFED GSVLKQFLSE TEKMSPEDRA KCFEKNEAIQ AAHDAVAQEG QCRVDDKVNF HFILFNNVDG HLYELDGRMP FPVNHGASSE DTLLKDAAKV CREFTEREQG EVRFSAVALC KAA
Explore Ubiquitin carboxyl-terminal hydrolase isozyme L1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets